LB Pharmaceuticals (LBRX) Leerink Global Healthcare Conference 2026 summary

Financial overview and capital strategy

• Raised $300 million in IPO and an additional $100 million through a PIPE, fully funding expansion into three programs.

• Access to capital as a public entity is enabling the advancement of multiple clinical trials.

• Recent capital raise supports initiation of an adjunctive MDD trial and global expansion.

Clinical development progress

• LB-102, a methylated derivative of amisulpride, shows improved CNS penetration and potency, with issued IP extending to 2041-2042.

• Phase 2 schizophrenia trial demonstrated statistically significant efficacy at all doses, with robust PANSS reduction and cognitive benefits.

• Phase 3 schizophrenia trial to start this month, targeting 460 patients at 25 U.S. sites, with data expected in H2 2027.

• Bipolar depression Phase 2 trial initiated, targeting 25 and 50 mg doses, with data expected Q1 2028.

• Adjunctive MDD Phase 2 trial planned for early 2027 start, enrolling 380 patients globally, with data in H1 2029.

Efficacy and safety highlights

• LB-102 achieved 70% dopamine receptor occupancy at 50 mg and 80% at 100 mg in Phase 1.

• Phase 2 schizophrenia trial showed a PANSS reduction of 14-16 points, moving patients from acute to stabilized states.

• Cognitive improvements were dose-dependent and statistically significant, with a treatment effect of 0.66 at 100 mg.

• Low rates of EPS and prolactin-related adverse events compared to amisulpride and other antipsychotics.

• Anxiety and insomnia rates were similar to placebo, with low discontinuation.